Sugi Predict

Sugi Predict / Compounds / SCHEMBL28269

SCHEMBL28269

SCHEMBL28269

O=C(O)[C@H]1C[C@@H](O)CN1C(=O)OCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ PSEN1 P49768 1/20 0.47
▸ PSEN2 P49810 1/20 0.47
▸ APH1B Q8WW43 1/20 0.47
▸ NCSTN Q92542 1/20 0.47
▸ APH1A Q96BI3 1/20 0.47
▸ PSENEN Q9NZ42 1/20 0.47
▸ ACE P12821 1/20 0.47
▸ AGTR2 P50052 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ PREP P48147 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7489292 1.00 POLB (0.62) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL31037789 1.00 POLB (0.62) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL115923 1.00 POLB (0.62) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL464289 1.00 POLB (0.62) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL7016734 1.00 POLB (0.62) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL71529 1.00 POLB (0.62) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL71528 1.00 POLB (0.62) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL29878 1.00 POLB (0.62) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL23485199 0.90 POLB (0.61) POLBSMN1; SMN2NPC1RAB9APSEN1
SCHEMBL30564487 0.90 POLB (0.61) POLBSMN1; SMN2NPC1RAB9APSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145644-A1 PROCESSES AND COMPOUNDS FOR PREPARING SPIROLIGOMERS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2025-05-08 — — US disclosed
CN-114591212-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2025-01-28 — — CN disclosed
EP-4475826-A2 PROCESSES AND COMPOUNDS FOR PREPARING SPIROLIGOMERS Temple University Of The Commonwealth System Of Higher Education (US) 2024-12-18 — — EP disclosed
CN-119032097-A Methods and compounds for preparing spiro oligomers 宾夕法尼亚州高等教育系统天普大学 2024-11-26 — — CN disclosed
US-20240300965-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-12 — — US disclosed
US-11999746-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-06-04 — — US disclosed
EP-4019022-B1 HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2024-01-31 — — EP disclosed
US-11807605-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807605-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807605-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-6201006-B1 ANTICOAGULANTS C & C RESEARCH LABORATORIES (KR) 2001-03-13 — — US disclosed
EP-0711755-B1 Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists LILLY CO ELI (US) 2000-05-31 — — EP disclosed
US-5942537-A ADMINISTERING A L-TRANS PYRROLIDINE DERIVATIVE TO INHIBIT THE TRANSPORT OF L-GLUTAMATE OR L-ASPARTATE OR AN EXCITATORY AMINO ACID NEUROTRANSMITTER AWAY FROM A SYNAPSE COMPRISING CONTACTING SYNAPSE WITH PYRROLIDINE DERIVATIVE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-08-24 — — US disclosed
EP-0918768-A1 AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS C & C Research Laboratories (KR) 1999-06-02 — — EP disclosed
WO-1997045424-A1 AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS C & C RESEARCH LABORATORIES (KR) 1997-12-04 — — WO disclosed
WO-1996015108-A1 PYRROLIDINYL DI-CARBOXYLIC ACID DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 1996-05-23 — — WO disclosed
EP-0711755-A1 Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists ELI LILLY AND COMPANY (US) 1996-05-15 — — EP disclosed
US-5473077-A 4-aminopyrrolidine-2,4-substitude independently with carboxylic acid or 5-tetrazolyl for treating nervous system disorders and psychological disorders ELI LILLY AND COMPANY (US) 1995-12-05 — — US disclosed
EP-0497895-A1 METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1992-08-12 — — EP disclosed
WO-1991006536-A1 METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1991-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300965-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B POLB 3233/4885SMN1; SMN2 1367/4885NPC1 304/4885
US-11999746-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B POLB 3233/4885SMN1; SMN2 1367/4885NPC1 304/4885
US-11807605-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 POLB 4045/4885SMN1; SMN2 3221/4885NPC1 473/4885
US-20250145644-A1 PROCESSES AND COMPOUNDS FOR PREPARING SPIROLIGOMERS PKD1, NPPA, REN POLB 3814/4885SMN1; SMN2 2781/4885NPC1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.